* Milestone Pharmaceuticals Inc MIST.OQ MIST.O is
expected
to show a fall in quarterly revenue when it reports results on
March 22 (estimated).
* The Montreal Quebec-based company is expected to report
a
60.5% decrease in revenue to $875 thousand from $2.22 million a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Milestone
Pharmaceuticals
Inc is for a loss of 33 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Milestone
Pharmaceuticals Inc is $16, above its last closing price
of $3.30.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Sep. 30 2022 -0.40 -0.41 -0.34 Beat 16.7
Jun. 30 2022 -0.34 -0.36 -0.39 Missed -8.3
Mar. 31 2022 -0.38 -0.39 -0.33 Beat 15.4
Dec. 31 2021 -0.36 -0.40 Missed -9.9
Sep. -0.40 -0.38 -0.34 Beat 11.5
30 2021
Jun. 30 2021 -0.27 -0.26 0.02 Beat 107.6
Mar. 31 2021 -0.32 -0.33 -0.30 Beat 8.5
Dec. 31 2020 -0.30 -0.41 -0.13 Beat 68
This summary was machine generated March 20 at 12:32 GMT. All
figures in US dollars unless otherwise stated